A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).

Trial Profile

A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 12 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 21 Sep 2015 Planned End Date changed from 1 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top